Introduction {#Sec1}
============

Gastric cancer represents a major public health issue as one of the most frequent cancers worldwide. The GLOBOCAN report of 2018, published by the World Health Organization (WHO), reported over 1 million new cases with 783,000 reported deaths worldwide, and gastric cancer was the third leading cause of death in 2018 \[[@CR1]\]. The incidence varies depending on sex (male-to-female ratio about 2:1) and between different geographic regions, with highest rates being recorded in East Asia and Eastern Europe. Despite improvements in surgical and perioperative management, gastric cancer still remains difficult to cure, mainly because of the absence of early clinical symptoms. Advanced gastric cancers typically present a poor prognosis with reported overall 5-year survival rates of only about 25% for European countries \[[@CR2]\].

Surgery is associated with complication rates ranging from 9--46% after total gastrectomy \[[@CR3], [@CR4]\], and occurrence of complications is known to adversely affect length of stay, readmission rates, quality of life, and costs \[[@CR5], [@CR6]\]. Most importantly, postoperative complications---in particular anastomotic leakage---impact on mortality, recurrence, and survival rates \[[@CR7], [@CR8]\]. Mechanisms by which postoperative complications affect patients' prognosis are not yet fully understood, but one potential reason might be that a prolonged inflammatory response in the context of complications could enhance residual tumor cell growth \[[@CR9]\]. Additionally, patients with severe complications are less likely to undergo adjuvant therapy, what may influence disease-free and overall survival as well \[[@CR3]\]. This relationship has only recently been analyzed by a Dutch group in their nationwide study, severe postoperative complications---besides weight loss and poor health status---had a threefold increased likelihood of omission of adjuvant treatment. Especially surgical complications in contrast to non-surgical complications resulted in omission of adjuvant chemotherapy (OR 3.4 vs. 1.9) \[[@CR10]\].

Therefore, stringent selection of patients for surgery might be a valuable tool for prevention of postoperative complications. This led to introduction of different classification systems for analysis of performance status, such as the "Karnofsky Index" or the "ASA (American Society of Anesthesiologists' Physical Status Classification Scale) Classification" into daily clinical practice. However, the major disadvantage of these non-specific scores is that they do not provide adequate risk assessment for patients undergoing complex surgeries \[[@CR11], [@CR12]\]. Hence, more specific risk scores have been developed for complex surgeries such as esophagogastric surgery, including the POSSUM Score (Physiological and Operative Severity Score for the enumeration of Mortality and Morbidity) \[[@CR13]--[@CR15]\], the "Cologne Risk Score" \[[@CR16]\], and the ACS NSQIP (American College of Surgeons National Surgical Quality Improvement Program) Surgical Risk Calculator \[[@CR17]\]. All these scores assess a number of perioperative organ functions and treatment details and are a popular tool to predict surgical risk. However, there is so-far only limited data available on the impact of these risk scores for outcome prediction in gastric cancer patients.

The present study now aimed to thoroughly assess the impact of preoperative patient-related risk factors and different (general and specific) risk scores on outcome after surgery for gastric cancer or cancers that invade the gastroesophageal junction and mandate extended gastrectomy \[Adenocarcinoma of the esophagogastric junction (AEG) II/III\]. For this purpose, the individual patient's risk was assessed via analysis of multiple aspects of patient's fitness and general condition, organ functions, as well as via different preoperative risk scores including the "Karnofsky Index", the "p-/o-POSSUM", "Cologne Risk Score", and NSQIP surgical risk. These data were compared with perioperative complications as per Clavien-Dindo classification.

Methods {#Sec2}
=======

Patient recruitment, preoperative workup, and staging {#Sec3}
-----------------------------------------------------

Between January 2006 and January 2017, all patients who underwent (extended/total/subtotal) gastrectomy for gastric cancer and AEG II/III tumors were enrolled into the study. Patients who underwent surgery with palliative intention were excluded from analysis of postoperative complications and survival. Furthermore, patients who underwent gastrectomy in combination with heated intraperitoneal chemotherapy (HIPEC) were excluded from the study.

Clinical investigations with regards to patient's general condition and fitness included comprehensive medical history, physical examination, blood tests, ECG, X-ray of the chest, anesthesiological consultation, and additional examinations as indicated. Preoperative tumor staging included an upper endoscopy (with biopsy and ultrasound) and CT-scan (thorax/abdomen/pelvis). Upon completion of the diagnostics, all patients were discussed in an interdisciplinary tumor board, and treatment intent and potential further investigations (e.g., laparoscopy) or neoadjuvant therapy were discussed and initiated. When neoadjuvant therapy was initiated, restaging investigations were performed to assess clinical response to treatment in order to exclude progressive disease or development of metastasis under pretreatment.

Standard surgical procedure and postoperative course {#Sec4}
----------------------------------------------------

Depending on tumor localization and size, staging results, and histological examination (Laurén-classification), either extended, total, or subtotal gastrectomy was performed. In case of curative intent, en bloc D2-lymphadenectomy was performed. To restore intestinal continuity, an end-to-side esophagojejunostomy or gastrojejunostomy with Roux-en-Y reconstruction was performed using a circular stapler in most cases. Routinely, patients received an epidural catheter for optimal analgesia, a gastric tube as well as an abdominal drain. Postoperatively, patients were extubated immediately and transferred to intermediate care unit for at least 1 day. Oral nutrition was started at day one with 400 ml fluids and was increased after the third postoperative day according to clinical progress. In addition, patients received total parenteral nutrition until enteral nutrition was sufficient. If anastomotic leakage was suspected, endoscopy was performed immediately. Otherwise, there was no routine control of the anastomosis such as Gastrographin swallow performed.

Study parameters {#Sec5}
----------------

All patients had a detailed preoperative assessment of their demographics, general condition, specific organ functions, tumor characteristics, treatment procedures, and the postoperative course according to the parameters as described below:

### Demographics, general conditions and specific organ functions {#Sec6}

Characteristics including age, gender, and patients' body mass index (BMI) were recorded. Potential body weight loss was categorized into weight loss \< 10%, 10--20%, and \> 20%. Alcohol intake was classified as "elevated alcohol consumption" when patients reported to drink more than one drink per day on a regular basis; in case of presence of alcohol-related organ damage, alcohol consumption was classified as "very elevated". Nicotine abuse was classified as follows: \< 5 cigarettes/day, 6--20 cigarettes/day, and \> 21 cigarettes/day. Assessment of specific organ functions included coronary heart disease, chronic heart failure, drug-treated hypertension, peripheral vascular disease, liver cirrhosis, dialysis-dependent renal failure, and diabetes mellitus. Data collection based on a questionnaire, a detailed medical history, and respective medical specialist reports. Additionally, spirometry was used to assess pulmonary function.

Preoperative general performance status {#Sec7}
---------------------------------------

Preoperative general performance status was assessed using different classification systems

### Clinical impression on first consultation {#Sec8}

The surgeon described his own impression of the patient's overall condition on the initial presentation in the outpatient clinic. For this purpose, the general condition was described as either "good", "reduced", or "poor", depending on presentation of the patient during the interview and clinical examination.

### Karnofsky performance status {#Sec9}

The Karnofsky index is an instrument to assess quality of life respectively to quantify activities of daily life \[[@CR18]\]. For this study, patients were classified into three groups: \> 80% (normal activity with effort, some symptoms of disease), = 70% (cares for him/herself, unable to carry on normal activity), or \< 60% (requires occasional assistance, but able to care for most of his/her personal needs).

### Cologne Risk score {#Sec10}

The "Preoperative risk analysis" published by Schroeder et al. enables estimation of the patient's general condition by considering several organ functions including pulmonary, cardiac, renal, and hepatic functions \[[@CR16]\]. The risk parameters are finally summarized in a total score allowing a categorization into three risk groups: "normal risk" (13--16 points), "moderately increased risk" (17--22 points), or "high risk" (23--38 points). Details of the comprehensive score are illustrated in Additional file [1](#MOESM1){ref-type="media"}.

### P- and o-POSSUM scores {#Sec11}

Both scores are based on the POSSUM score, which analyzes 12 physiological/clinical parameters (age, cardiac function, respiratory function, ECG, systolic blood pressure, pulse rate, hemoglobin levels, white blood count, urea levels, sodium levels, potassium levels, and Glasgow Coma Scale). Besides these parameters, the p-POSSUM score takes six operative parameters into account (operation type, multiple procedures, total blood loss, presence of malignancy, peritoneal seeding, and mode of surgery) and allows prediction of morbidity and mortality. The o-POSSUM score was derived to provide a dedicated scoring system for esophageal and gastric surgeries. In contrast to the p-POSSUM score, operative blood loss and number of procedures were excluded from multivariate analysis. While the p-POSSUM score predicts postoperative morbidity and mortality, the o-POSSUM scores predicts postoperative mortality only \[[@CR15]\].

### NSQIP risk score {#Sec12}

Based on the 21 preoperative patient characteristics such as age, ASA, BMI, and comorbidities, the ACS NSQIP universal risk calculator estimates the chance of 15 unfavorable outcomes such as complication or death following surgery \[[@CR17]\].

Tumor characteristics {#Sec13}
---------------------

Based on the preoperative tumor staging as described above, characteristics of the tumor including histology (EAC/adenosquamous carcinoma), location (cardia, body, fundus, antrum/pylorus), Laurén classification, tumor size, tumor stage, nodal stage, and presence of metastasis were recorded. Postoperatively, tumor stage was assessed by the 7th UICC TNM staging. T, N, and M categories as well as the resection margins, the histological grading, vein and lymph node invasion, and number of involved and resected lymph nodes were recorded. When neoadjuvant therapy was administered, pathologic response was categorized in tumor regression grades according to Baldus.

Treatment details {#Sec14}
-----------------

### Neoadjuvant therapy and clinical response {#Sec15}

Depending on preoperative tumor staging, neoadjuvant therapy was initiated in patients with locally advanced but potentially curable cancers if patients were deemed fit for pretreatment. Neoadjuvant treatment was initiated in form of chemotherapy in most cases. Chemotherapy was administered according to the ECF (epirubicin, cisplatin, 5FU), FLOT (oxaliplatin, docetaxel, leucovorin, 5FU), EOX (epirubicin, oxaliplatin, capecitabine), or PLF (cisplatin, leucovorin, 5FU) protocols. Only three patients (with AEG tumors) received neoadjuvant radiochemotherapy. Clinical response was assessed by restaging investigations: patients with a significant decrease of the tumor diameter measured on the CT scan respectively of the endoluminal tumor size as visualized by endoscopy were classified as "Clinical responders" or, otherwise, as "Clinical non-responders". Parameters of surgical treatment included intention of surgery (palliative/curative), procedure (subtotal/extended/gastrectomy) technique of anastomosis (hand/stapler) and intraoperative blood loss.

Postoperative course {#Sec16}
--------------------

Postoperatively, length of stay, occurrence of complications, in-hospital mortality, overall survival, and disease-free survival were recorded. Patients who underwent gastrectomy in palliative intention were excluded from analysis. Furthermore, patients who died during their stay in hospital (= in-hospital mortality) were excluded for calculation of long-term survival.

Classification of surgical complications {#Sec17}
----------------------------------------

The perioperative surgical complications were assessed based on the Clavien-Dindo classification and therefore defined as "any deviation from the normal postoperative course" \[[@CR19]\]. In clinical everyday life, grades III and IV complications are of high importance because these complications require immediate surgical, endoscopic, or radiological interventions, or mandate treatment of single or multi-organ failure in intensive care units. Therefore, complications were classified as follows: no complications (grade 0), minor complications (grade I and II), and major complications (grade III-V).

Statistical analysis {#Sec18}
--------------------

All data are presented as means with standard deviation unless otherwise stated. Statistical analysis was performed with SPSS 25.0 (SPSS, Chicago, USA) by using Chi-square tests for categorical variables, Pearson's correlation for numeric variables, and one-way ANOVA / Kruskal--Wallis for numeric versus categorical variables. The Kaplan--Meier method with log-rank tests was used for assessment of overall and disease-free survival. A *p* value \< 0.05 was considered to be statistically significant.

Results {#Sec19}
=======

Demographics and physical condition including risk classification {#Sec20}
-----------------------------------------------------------------

During the study period, a total of 139 patients with a mean age of 64 years old (24--91 years old) were enrolled into the study. Sixty nine percent of these patients were men. The majority of the study population (40%) was treated because of a carcinoma located in the corpus. Further details of the tumor characteristics are presented in Table [1](#Tab1){ref-type="table"}. Preoperative physical condition, co-morbidities, respectively, other patient-related risk factors are presented in Table [2](#Tab2){ref-type="table"}. The most frequent co-morbidities patients suffered from were cardiovascular diseases. In contrast, hepatic diseases for example were extremely rare. Only 11% of the study population did not suffer from any co-morbidity. Table [3](#Tab3){ref-type="table"} shows the patients' distribution into the different risk groups according to Karnofsky and the Cologne Risk Score as well as the predicted morbidity/mortality rates calculated by p-/o-POSSUM while the surgical risk based on the NSQIP calculator is shown in Fig. [1](#Fig1){ref-type="fig"}. Table 1Demographics and clinic-pathologic characteristics (*n* = 139)CharacteristicsNumber of patientsPercentagePreoperative tumor findings Mean age64 (24--91) years old Gender  Male9669.1%  Female4330.9% Localization  Cardia3827.3%  Corpus5539.2%  Fundus32.2%  Antrum/pylorus4330.9% Histology  Adenocarcinoma13899.3%  Adenosquamous carcinoma10.7% Laurén-classification  Intestinal5438.8%  Diffuse5841.7%  Mixed128.6% Tumor stage  uT11611.5%  uT23827.3%  uT37251.8%  uT496.5% Nodal stage  uN positive6949.6%  uN negative6949.6% Metastasis  M012690.6%  M1117.9%  Mx21.4% Mean tumor size3 (0.2--30) cm Neoadjuvant therapy  Yes5741%  No8259%Treatment Response to neoadjuvant therapy (*n* = 57)  Clinical response (yes)4375.4%  Clinical response (no)1424.6%  Pathologic response (yes)3154%  Pathologic response (no)2645.6% Intention  Curative12086.3%  Palliative1913.7% Timing  Elective13899.3%  Emergency10.7% Procedure  Subtotal3223%  Gastrectomy8259%  Extended2518% Intraoperative blood loss  ≤ 100 ml4129.5%  101--500 ml6647.5%  501--1000 ml2920.9%  ≥ 1001 ml32.2% Anastomosis  Stapler9669.1%  Hand suture4330.9%Postoperative tumor findings Tumor stage  (y)pT064.3%  (y)pTis10.7%  (y)pT12618.7%  (y)pT23021.6%  (y)pT34733.8%  (y)pT42920.9% Nodal stage  N06244.6%  N13525.2%  N21611.5%  N32618.7% Metastasis  M012287.8%  M11510.8% Resection margin  R012287.8%  R11510.8%  R221.4% Histological grading  G075%  G142.9%  G22518%  G39366.9% Lymph nodes removed (mean)23 (4--60)  Lymph node invasion  L08762.6%  L14532.4% Invasion into vein  V011381.3%  V11913.7%Median hospital stay (range)14 (1--120) daysIn-hospital mortality42.9%Survival rate5.6 yearsRecurrence (*n* = 120) Yes4136.9% No6962.2%Recurrence-free survival3.4 years Table 2Preoperative patient conditions and patient-related risk factorsVariablesPatientsPercentageCoronary heart disease Yes2115.1% No11884.9%Heart insufficiency No11280.6% Yes2719.4%Drug-treated hypertension Yes6043.2% No7956.8%Arterial occlusive disease Yes64.3% No13395.7%Vital capacity \> 90%10877.7% 71--90%2215.8% ≤ 70%96.5%FEV1 \> 80%11381.3% 61--80%1510.8% ≤ 60%117.9%Liver cirrhosis None13697.8% Child A21.4% Child B10.7% Child C00Creatinine Clearance \> 95 ml/min12589.9% ≤ 95 ml/min1410.1%Dialysis-dependent kidney insufficiency Yes32.2% No13697.8%Insulin-dependent diabetes mellitus Yes1410.1% No12589.9%BMI 20--256848.9% 25.1--304733.8% \> 30.12417.3%Weight loss \< 10%10877.7% 10.1--20%2719.4% \> 20.1%42.9%Alcohol consumption Normal12589.9% Elevated128.6% Very elevated21.4%Nicotine abuse/day \< 5 cigarettes10374.1% 6--20 cigarettes2518% \> 21 cigarettes117.9% Table 3Risk scores as potential predictorsVariablesPatientsPercentagePatient's general condition Good9669.1% Reduced3726.6% Poor64.3%Karnofsky index \> 8011985.6% 70%1410.1% \< 60%64.3%Cologne Risk score Normal risk3122.3% Moderate risk6949.6% High risk3928.1%POSSUM score (Morbidity) 0--10%10.7% 10.1--20%2518% 20.1--30%2417.3% 30.1--40%2316.5% 40.1--50%85.8% 50.1--60%2014.4% 60.1--70%1510.8% 70.1--80%64.3% 80.1--90%96.5% 90.1--100%85.8%POSSUM score (Mortality) 0--2%7151.1% 2.1--4%2215.8% 4.1--6%1913.7% 6.1--8%53.6% 8.1--10%32.2% \> 10%1913.7%O-POSSUM score (Mortality) \< 1%13395.7% 1--2%64.3% Fig. 1Estimated risk of any / serious complications respectively death estimated by the NSQIP risk score calculator

Treatment, surgical details, and postoperative tumor characteristics {#Sec220}
--------------------------------------------------------------------

Fifty seven (41%) patients underwent neoadjuvant treatment \[54 patients received neoadjuvant chemotherapy and 3 patients (with AEG II tumors) received neoadjuvant radiochemotherapy\]. Following neoadjuvant treatment, 75% of the patients were classified as responders (= clinical response). Surgery was performed with curative intent in the majority of patients (86.3%). The main reason for palliative gastrectomy was bleeding. Subtotal gastrectomy was performed in 23%, gastrectomy in 59%, and extended gastrectomy in 18% of the patients using a stapler for anastomosis in 69%. For further details and postoperative tumor findings, see Table [1](#Tab1){ref-type="table"}.

Outcome: morbidity and mortality {#Sec21}
--------------------------------

Only patients that underwent surgery with curative intention were included for further analysis (*n* = 120). Forty percent of the patients did not suffer from any postoperative complication. See Table [4](#Tab4){ref-type="table"} for distribution of the patients according to Dindo. The median in-hospital stay was 14 days. In case of complications, hospital stay was prolonged (no complications: 12 days, I-II: 15 days, III-V: 32 days; *p* \< 0.001). Table 4Postoperative complications according to Clavien-Dindo (patients who underwent surgery in palliative intention were excluded from analysis, *n* = 120)Patients\
(*n* = 120)PercentageClavien-Dindo None4840% I2319.2% II2016.7% III2016.7% IV65% V32.5%Morbidity Yes7260% No4840%

Impact of demographics and tumor characteristics on morbidity and mortality {#Sec22}
---------------------------------------------------------------------------

Age was identified as most important risk factor. The higher the patients' age, the higher the chance of occurrence of complications (*p* = 0.001), overall morbidity (*p* = 0.005), mortality (*p* = 0.042) as well as with length of hospital stay (*p* = 0.008). Moreover, localization of the tumor as well as the uT-/M-stage impacted on complication and mortality rates: a significant increased risk was observed when the tumor was located in the cardia while the risk was lower for tumors located in the antrum (morbidity: *p* = 0.039, mortality: *p* = 0.006). A significant increased risk was also observed for patients suffering from higher uT-/M-stages (morbidity: uT-/M *p* = 0.022/0.001, mortality: uM-stage *p* \< 0.001).

Impact of treatment and postoperative tumor staging on morbidity and mortality {#Sec23}
------------------------------------------------------------------------------

The type of surgical procedure impacted on the occurrence of complications with extended gastrectomy showing the highest risk of complications (*p* = 0.005) but not on mortality rates. Morbidity and mortality rates were independent from intraoperative blood loss, timepoint of surgery, or technique of anastomosis, though. Furthermore, complication and mortality rates were neither associated with administration of neoadjuvant (R)CT (morbidity: *p* = 0.082, mortality: *p* = 0.811), postoperative tumor staging, nor with clinical or pathologic response.

Impact of patient-related risk factors and risk scores on morbidity and mortality {#Sec24}
---------------------------------------------------------------------------------

Neither the Karnofsky index nor the patient's general condition correlated with occurrence of complications (*p* \> 0.096). Regarding the scoring systems, mean morbidity rates were predicted as follows: p-POSSUM: 43%, NSQIP serious complications: 21%. The observed incidence of overall morbidity was 60%, respectively 21% for serious complications (Dindo III/IV) and therefore exactly as predicted by the NSQIP score. In correlation analysis, we observed a highly positive correlation between predicted morbidity and occurrence of complications estimated by the p-POSSUM (*p* = 0.005) and NSQIP score (*p* \< 0.001, Fig. [2](#Fig2){ref-type="fig"} a, b). In line with these findings, similar observations have been made for increasing preoperative risk according to the Cologne Risk score and increasing severity of postoperative complications (*p* = 0.007, Fig. [2](#Fig2){ref-type="fig"}c). Fig. 2Correlation between preoperative risk as assessed according to p-POSSUM (**a**), NSQIP risk score (serious complications) (**b**) and Cologne risk score (**c**) and severity of postoperative complications as assessed via the Dindo classification

We did not observe a correlation between Karnofsky index, the patient's general condition, nor the o-POSSUM score and mortality rates. The expected mortality rates predicted by the three other scoring systems were as follows: p-POSSUM: 4.4%, o-POSSUM: 0.36%, and NSQIP: 1.8%, while the observed incidence of mortality was 2.5%. Therefore, p-POSSUM overestimated mortality rates while the two other scores underestimated mortality, especially the o-POSSUM score. Correlation analysis showed a positive correlation between predicted mortality calculated by NSQIP score (*p* \< 0.001) and p-POSSUM (*p* = 0.006) and death.

Overall survival and disease-free survival {#Sec25}
------------------------------------------

We observed a mean survival of 5.6 years. Survival rates correlated with localization (lowest overall survival when tumor was located in the cardia, *p* = 0.003), uN (*p* = 0.002), BMI (*p* = 0.024), weight loss (*p* = 0.001), smoking (*p* = 0.025), Karnofsky (*p* = 0.035), general status (*p* \< 0.001), p-POSSUM morbidity and mortality (*p* = 0.019; *p* = 0.002), NSQIP scores (*p* \< 0.004), type of surgery (*p* = 0.003), pT/N/L/V (*p* \< 0.001), *R* (*p* = 0.12), and pathologic response (*p* = 0.002). Occurrence of complications shortened overall survival: e.g., patients suffered from a Dindo III/IV complication only showed an overall survival of 3.9 years (*p* = 0.05). Interestingly, patients who were attributed to the normal risk group according to the Cologne Risk score had an overall survival of 7.4 years while patients from the high-risk group only had survival rates of 3.6 years (*p* = 0.011).

Forty one patients (36.9%) suffered from recurrence; mean disease-free survival was 3.4 years (52--3782 days). Disease-free survival rates correlated with age (*p* = 0.049), localization of the tumor with shorter disease-free survival when located in the cardia (*p* \< 0.001), uN (*p* = 0.002), length of tumor (*p* \< 0.001), general status (*p* = 0.002), Karnofsky (*p* = 0.047), weight loss (*p* = 0.001), Cologne Risk score (*p* = 0.031), p-POSSUM morbidity (*p* \< 0.001), NSQIP scores (*p* \< 0.017), pT/N (*p* \< 0.001), and pathologic response (*p* = 0.002).

Discussion {#Sec26}
==========

Postoperative complications are known to influence outcome of patients undergoing gastrectomy, and despite improvements in surgical technique and perioperative management, surgery still bears relevant morbidity \[[@CR3], [@CR7]\]. High morbidity rates are also attributed to high numbers of elderly patients and patients in poor health that undergo extensive surgical procedures. Therefore, identification of patients with high risk for postoperative complications is of utmost importance in order to improve clinical decision-making with regards to personalized individual treatment planning. In this context, preoperative risk prediction using specific risk score such as the Cologne Risk score, the p-/o-POSSUM prediction models, or the NSQIP risk calculator might be of relevance. The current study aimed to thoroughly analyze the potential of general aspects such as demographics, tumor stage, physical condition, or co-morbidities as well as the potential of esophagogastric-specific preoperative risk scores to predict outcome after surgery for gastric cancer.

In contrast to unspecific performance status scores such as the Karnofsky index, which failed to predict outcome in our study population, we observed a significant correlation between the preoperatively estimated risk as calculated by the NSQIP score and morbidity and mortality. The estimated chance of serious complications for example was 21%, which was exactly in accordance with the observed incidence of serious complications. Mortality rates were slightly underestimated (estimated 1.8%, observed 2.5%). So far, the applicability of the NSQIP score, which was introduced in 2013, to patients undergoing gastrectomy has been assessed by only one other study, to the best of our knowledge \[[@CR20]\]. In this multicenter study, Beal et al. included 965 patients who underwent resection of gastric adenocarcinoma and found variable results in terms of accuracy of the estimated risk. For example, highest correlation rates were observed for venous thromboembolism and lowest for renal failure. The authors conclude that the risk calculator represents a promising tool for risk prediction but needs further validation \[[@CR20]\]. Despite limiting data regarding esophagogastric patients, the ACS NSQIP risk calculator was evaluated for a broad range of various study populations, ranging from head and neck cancer patients \[[@CR21]\] to patients who underwent cystectomy \[[@CR22]\]. Results of these studies were ambiguous: while the risk score demonstrated low accuracy in predicting postoperative outcomes in some cohorts \[[@CR22], [@CR23]\], it was considered as a reliable tool in the prediction of prognosis in other study populations \[[@CR21], [@CR24]\], suggesting that further studies are needed for validation.

Furthermore, we analyzed prediction models that were developed for esophagogastric surgery such as the Cologne Risk score. Latter was identified as accurate predictor of outcome in our study population. This score was first described by Schroeder et al. who demonstrated a correlation between the risk score and outcome of patients undergoing esophageal resection \[[@CR16]\]. Our current results underline this hypothesis and are consistent with previous findings from our group for esophageal cancer surgery \[[@CR25]\].

Also known as risk score for prediction of outcome following complex surgery is the POSSUM score, which was also considered in this study. Numerous authors investigated the potential of this well-known score in cancer patients within recent years, and some authors found an overestimation of risk by the factor two to three \[[@CR26]\], especially in low-risk patients \[[@CR27]--[@CR29]\]. This observation led to the introduction of modifications of the POSSUM scoring system such as p-/o-POSSUM that consider operative parameters. Unfortunately, data on esophagogastric cancer patients are limited \[[@CR30]\] and available data with regards to their potential to predict outcome are inconclusive. For example, Hong et al. identified p-/o-POSSUM as better predictors of postoperative mortality compared to POSSUM score \[[@CR31]\]. In a review article that summarized 10 relevant publications, p-POSSUM showed the least overestimation compared to POSSUM and o-POSSUM scores and was therefore considered as most useful predictor of mortality \[[@CR29]\]. In contrast, Bosch et al. showed that mortality after esophagectomy was best predicted by o-POSSUM, despite the fact that postoperative mortality was still overpredicted \[[@CR32]\]. This observation is in line with findings from Gocmen et al. \[[@CR33]\]. Other authors, however, resumed that the p-/o-POSSUM model is not a suitable tool to predict postoperative mortality following esophagogastric cancer resections accurately \[[@CR34], [@CR35]\].

In our study, o-POSSUM also failed to predict mortality, while p-POSSUM correlated with morbidity and mortality rates. However, the score underestimated morbidity (predicted: 43%, observed: 60%) and overestimated mortality (predicted: 4.4%, observed: 2.5%), as described by others \[[@CR15]\]. However, it has to be considered that morbidity of 60% represents overall morbidity including Dindo I, which represent complications that do not require any particular therapy. Exclusion of Dindo I complications results in an observed morbidity rate of 40%, which is similar to the predicted morbidity estimated by p-POSSUM. It is also important to mention, though, that the p-POSSUM score also includes several operative parameters such as intraoperative blood loss. Hence, this score is in contrast to the NSQIP and Cologne Risk score and not a helpful tool for selection of patients preoperatively.

There are some limitations of the current study that need consideration. First, the current study is a retrospective cohort study on what causes a number of well-known limitations including for example the problem of incomplete or inconsistent acquisition of data. Second, the study is a single-center study with a limited number of patients. Summarized, a prospective study including a larger patient cohort is mandatory to confirm the current results, especially because of conflicting data regarding the potential of the different scores to predict outcome accurately as described above.

Conclusion {#Sec27}
==========

The current study demonstrates a significant association between different risk scores and occurrence of complications following gastrectomy for gastric adenocarcinoma and AEG II/III tumors. Unspecific scores such as Karnofsky do not allow accurate prediction of outcome. In our study population, the Cologne Risk score and the NSQIP risk score exhibited superior performance than the o-POSSUM score. Our data clearly support the use of various parameters and scores for better patient selection and clinical decision making with the goal to reduce perioperative morbidity and mortality.
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 {#Sec28}

**Additional file 1.** Cologne Risk score.

ACS NSQIP

:   American College of Surgeons National Surgical Quality Improvement Program

AEG

:   Adenocarcinoma of the esophagogastric junction

ASA

:   American Society of Anaesthesiologists' Physical Status Classification Scale
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:   Body mass index
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:   Forced expiratory volume
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:   Heated intraperitoneal chemotherapy

OR

:   Odds ratio
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